|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Nathaniel E. David||Co-Founder, Pres & Exec. Director||640,86k||N/D||1968|
|Mr. Robert C. Goeltz II||Chief Financial Officer||577,3k||N/D||1973|
|Dr. Anirvan Ghosh||Director & CEO||N/D||N/D||1964|
|Dr. Jan M. van Deursen||Founder||N/D||N/D||N/D|
|Dr. Judith Campisi||Founder||N/D||N/D||N/D|
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in Brisbane, California.
L'ISS Governance QualityScore di Unity Biotechnology, Inc. al 7 dicembre 2019 è 9. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 10; diritti degli azionisti: 8; retribuzione: 9.